This is why PAK1 inhibitors can significantly enhance the therapeutic effect of EGFR-TKI inhibitors in EGFR-TKI-resistant non-small cell lung cancer and lung adenocarcinoma 68, 69. Here, EGFR is linked to lung adenocarcinoma.